1. Home
  2. SIBN vs GERN Comparison

SIBN vs GERN Comparison

Compare SIBN & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SI-BONE Inc.

SIBN

SI-BONE Inc.

HOLD

Current Price

$15.40

Market Cap

886.9M

Sector

Health Care

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.62

Market Cap

900.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SIBN
GERN
Founded
2008
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
886.9M
900.1M
IPO Year
2018
1996

Fundamental Metrics

Financial Performance
Metric
SIBN
GERN
Price
$15.40
$1.62
Analyst Decision
Strong Buy
Buy
Analyst Count
8
7
Target Price
$25.00
$3.00
AVG Volume (30 Days)
535.0K
13.8M
Earning Date
02-23-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$193,578,000.00
$183,403,000.00
Revenue This Year
$21.95
$146.80
Revenue Next Year
$15.02
$30.21
P/E Ratio
N/A
N/A
Revenue Growth
23.27
522.13
52 Week Low
$12.50
$1.04
52 Week High
$21.89
$2.96

Technical Indicators

Market Signals
Indicator
SIBN
GERN
Relative Strength Index (RSI) 25.63 68.06
Support Level $15.06 $1.45
Resistance Level $16.86 $1.58
Average True Range (ATR) 0.53 0.09
MACD -0.09 0.02
Stochastic Oscillator 15.73 97.10

Price Performance

Historical Comparison
SIBN
GERN

About SIBN SI-BONE Inc.

SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Share on Social Networks: